Draft Guidance On Developing Drug Names Calls For Simulation Studies
This article was originally published in The Tan Sheet
Executive Summary
FDA’s draft guidance on developing proprietary drug names recommends steps to evaluate a proposed name, including testing names with health care professionals. The draft notes that OTC “brand name extensions have posed problems when the same root proprietary name is used for multiple products.”
You may also be interested in...
Concerned By Confusion Over OTC Drug Brands, US FDA Offers Guidance On Developing Names
Extending an OTC brand name to a product with a different active ingredient and indication creates a margin for error in the marketplace, FDA says. Recommendations include best practices to help minimize name-related medication errors and a framework FDA uses in evaluating proposed propriety names.
PhRMA Seeks Repeal Of Brand Name Review Rule Until A Benefit Is Shown
The pharmaceutical industry wants FDA to prove its proprietary name review program is worth the effort.
Novartis' Maalox Total Relief Rebranding Reflects FDA AER Evolution
FDA's request that Novartis rebrand a Maalox line extension is the latest illustration of the agency taking action based on a relatively small number of serious adverse event reports